Observational prospective study in post-menopausal women with advanced HR+/HER2- breast cancer treated with a combination of Afinitor® + exemestane to describe the management of two Adverse Events, non-infectious lung disease and stomatitis (TANGO) First published 02/09/2014 Last updated 14/03/2024 EU PAS number:EUPAS7325 Study Finalised